8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 26, 2026·SEC
Material company update
Mar 12, 2026·SEC
Century Therapeutics, Inc.(IPSC)Earnings, Financials & Key Ratios
IPSC•NASDAQ
$2.31
Price updated Jul 7, 2026
AboutCentury Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.Show more
- Revenue$109M+1556.8%
- EBITDA-$2M+98.4%
- Net Income-$10M+92.4%
- EPS (Diluted)-0.11+93.2%
- Gross Margin88%-12.0%
- EBITDA Margin-1.78%+99.9%
- Operating Margin-13.78%+99.3%
- Net Margin-8.78%+99.5%
- ROE-5.98%+91.8%
IPSC Price & Volume
Century Therapeutics, Inc. (IPSC) stock price & volume — 10-year historical chart
Loading chart...
Episodic Milestone Revenue Masks Persistent Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical milestone dependency risk
Key Thesis Takeaways
- Century Therapeutics faces a challenging outlook characterized by high clinical development costs and a reliance on volatile, non-recurring milestone payments to sustain its allo-evasion platform.
- While the company maintains a current ratio of 10.25, the rapid erosion of its asset base from $416.4 million in 2024Q2 to $326.6 million in 2026Q1 suggests significant long-term funding risks.
- Investors should monitor the company's ability to secure additional capital, as the current cash position of $51.0 million appears insufficient to support sustained R&D expenditures that frequently exceed $20 million per quarter.
Verdict Logic
the company's precarious liquidity position, evidenced by a cash balance of only $51.0 million against quarterly R&D expenses often exceeding $20 million, suggests a high probability of future shareholder dilution.
IPSC Growth Metrics
Century Therapeutics, Inc. (IPSC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years175.88%
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-391.11%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-290.63%
Return on Capital
10 Years-33.77%
5 Years-31.94%
3 Years-30.83%
Last Year-7.05%
IPSC Recent Earnings
Century Therapeutics, Inc. (IPSC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 4/12 qtrs (50%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.11+26.7%
$0.15
Rev
—
$3M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.25+10.7%
$0.28
Rev
—
$62,500
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.32+17.9%
$0.39
Rev
—
$83,330
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.38+0.0%
$0.38
Rev
—
$25,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.11vs $0.15+26.7% | —vs $3M |
| Q2 2026 | Mar 12, 2026 | $0.25vs $0.28+10.7% | —vs $62,500 |
| Q4 2025 | Nov 13, 2025 | $0.32vs $0.39+17.9% | —vs $83,330 |
| Q3 2025 | Aug 14, 2025 | $0.38vs $0.38+0.0% | —vs $25,000 |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Century Therapeutics, Inc. (IPSC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.31 | $199.98M | -21.00 | 1556.76% | -8.78% | -5.98% | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — | |
| $115.72 | $5.64B | -30.61 | — | — | -244.61% | — | |
| $4.35 | $1.56B | -3.99 | 60.6% | -123.9% | -50.17% | — | |
| $60.77 | $5.86B | -9.39 | -89.97% | -13856.54% | -30.88% | — |
Compare IPSC vs Peers
Century Therapeutics, Inc. (IPSC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IPSC SEC Filings & Documents
Century Therapeutics, Inc. (IPSC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when IPSC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IPSC Frequently Asked Questions
Century Therapeutics, Inc. (IPSC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Century Therapeutics, Inc.'s revenue?
Century Therapeutics, Inc. (IPSC) reported $109.2M in revenue for fiscal year 2025.
How fast is Century Therapeutics, Inc. growing?
Century Therapeutics, Inc. (IPSC) grew revenue by 1556.8% over the past year. This is strong growth.
Is IPSC profitable?
Century Therapeutics, Inc. (IPSC) reported a net loss of $107.8M for fiscal year 2025.
Dividend & Returns
What is IPSC's return on equity?
Century Therapeutics, Inc. (IPSC) has a return on equity (ROE) of -6.0%. Negative ROE indicates the company is unprofitable.
What is Century Therapeutics, Inc.'s free cash flow?
Century Therapeutics, Inc. (IPSC) had negative free cash flow of $95.9M in fiscal year 2025, likely due to heavy capital investments.